Antimetabolites, in particular nucleobase and nucleoside analogues, are cytotoxic drugs
that, starting from the small field of paediatric oncology, in combination with other …

Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of
malignant transformation of mature lymphocytes during various stages of differentiation. The …

The altered expression of SHP-1 (SH2 domain-containing protein tyrosine phosphatase) as
a consequence of promoter hypermethylation or mutations has evidently been linked to …

The maturation of B cells is a complex, multi-step process. During B cell differentiation,
errors can occur, leading to the emergence of aberrant versions of B cells that, finally …

Combination chemotherapy has proven to be a favorable strategy to treat acute leukemia.
However, the introduction of novel compounds remains challenging and is hindered by a …

Chronic myeloid leukemia (CML) therapy has markedly improved patient prognosis after
introduction of imatinib mesylate for clinical use. However, a subset of patients develops …

The remarkable evolutionary capacity of cancer is a major challenge to current therapeutic
efforts. Fueling this evolution is its vast clonal heterogeneity and ability to adapt to diverse …

Mass spectrometry-based quantitative proteomics specifically applied to comprehend the
pathogenesis of lymphoma has incremental value in deciphering the heterogeneity in …

Nucleobase and nucleoside analogs (NAs) play important roles in cancer therapy. Although
there are obvious individual differences in NA treatments, most NAs lack direct relationships …

Chronic myeloid leukemia (CML) is a myeloproliferative stem cell disease characterized by
the expression of BCR-ABL oncoprotein with constitutive tyrosine kinase activity. Although …